- Home
- IVR vs RGNX Comparison
IVR vs RGNX Comparison
Compare IVR & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVR
- RGNX
- Stock Information
- Founded
- IVR 2008
- RGNX 2008
- Country
- IVR United States
- RGNX United States
- Employees
- IVR N/A
- RGNX N/A
- Industry
- IVR Real Estate Investment Trusts
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVR Real Estate
- RGNX Health Care
- Exchange
- IVR Nasdaq
- RGNX Nasdaq
- Market Cap
- IVR 515.0M
- RGNX 459.1M
- IPO Year
- IVR 2009
- RGNX 2015
- Fundamental
- Price
- IVR $8.38
- RGNX $7.62
- Analyst Decision
- IVR Buy
- RGNX Strong Buy
- Analyst Count
- IVR 2
- RGNX 12
- Target Price
- IVR N/A
- RGNX $36.00
- AVG Volume (30 Days)
- IVR 1.3M
- RGNX 1.7M
- Earning Date
- IVR 11-05-2024
- RGNX 11-06-2024
- Dividend Yield
- IVR 19.12%
- RGNX N/A
- EPS Growth
- IVR N/A
- RGNX N/A
- EPS
- IVR 1.23
- RGNX N/A
- Revenue
- IVR $102,893,000.00
- RGNX $84,327,000.00
- Revenue This Year
- IVR N/A
- RGNX $2.34
- Revenue Next Year
- IVR $6.62
- RGNX $243.67
- P/E Ratio
- IVR $6.81
- RGNX N/A
- Revenue Growth
- IVR 654.96
- RGNX N/A
- 52 Week Low
- IVR $7.60
- RGNX $7.21
- 52 Week High
- IVR $9.97
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- IVR 49.61
- RGNX 36.08
- Support Level
- IVR $8.17
- RGNX $8.06
- Resistance Level
- IVR $8.65
- RGNX $10.52
- Average True Range (ATR)
- IVR 0.18
- RGNX 0.76
- MACD
- IVR -0.01
- RGNX -0.19
- Stochastic Oscillator
- IVR 48.19
- RGNX 12.39
About IVR INVESCO MORTGAGE CAPITAL INC
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.